The National Center for Global Health and Medicine has announced the results of a clinical study showing that more than 70% of people who received the vaccine were able to obtain sufficient antibodies regarding the effectiveness of the ``Mpox'' vaccine against monkeypox.
The research group has confirmed the efficacy and safety of the drug, and plans to investigate its effects on people with weakened immune systems.
A group led by Dr. Mugen Ujiie of the National Center for Global Health and Medicine inoculated 50 medical institution staff with a vaccine developed by a Japanese pharmaceutical company as a smallpox vaccine and also approved for Empox to determine its effectiveness and safety. We conducted a clinical study to confirm the sex.
According to the results, the amount of antibodies after vaccination increased over time, and four weeks later, more than 70% of people had detected enough antibodies to suppress the virus.
Additionally, the research group concluded that ``the efficacy and safety have been confirmed once again'' as no serious side effects were reported.
On the other hand, the percentage of people with sufficient antibodies decreased to about 30% nearly half a year after vaccination, and Dr. Ujiie, who led the study, said, ``The only thing we knew was how the amount of antibodies obtained changed over time.'' "This is the first time we've tried it, so we need to verify how it affects its effectiveness."
As of the 8th of this month, there have been a total of 242 Empox patients in Japan, and the group plans to increase the number of research subjects in the future, including those infected with HIV (Human Immunodeficiency Virus), who have weakened immune systems. We will also investigate the effects on people who are at high risk, such as patients.
Expert: ``It's very effective in preventing infection and disease.''
Regarding this research, Professor Shigeru Morikawa of Okayama University of Science, who is familiar with M-pox, said, ``Compared to the data on the smallpox virus, this data suggests that this vaccine is sufficiently effective in preventing M-pox infection and onset. "Additional vaccinations may be necessary in order to maintain the antibodies that decrease over time."